| abstract |
Herein,n n n a) one or more antigens associated with an undesirable immune response and / or regeneration process,n n n b) one or more protein synthesis inhibitors, and optionallyn n n c) Pharmaceutical formulations are described for the treatment of transient, impaired immune responses and degenerative processes, including active compounds that inhibit acute inflammatory responses. |